SEC Form 4 · accession 0001638599-17-001129
SELECTA BIOSCIENCES INC · SELB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy A Springer
Director
Period of report
Nov 9, 2017
Accepted (ET)
Nov 13, 2017 · 6:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001453687
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 9, 2017 | P | 21,100 | $9.3314 | A | 376,513 | D | |
| Common StockF2 | Nov 9, 2017 | P | 900 | $9.7407 | A | 377,413 | D | |
| Common StockF3 | Nov 9, 2017 | P | 4,900 | $9.3271 | A | 4,900 | I | By wife |
| Common Stock | Nov 9, 2017 | P | 100 | $9.78 | A | 5,000 | I | By wife |
| Common StockF4 | Nov 10, 2017 | P | 21,586 | $9.0425 | A | 398,999 | D | |
| Common StockF5 | Nov 10, 2017 | P | 4,752 | $9.029 | A | 403,751 | D | |
| Common StockF6,F7 | holding | — | — | — | 1,237,028 | I | See Footnote | |
| Common StockF6,F8 | holding | — | — | — | 445,576 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.72 to $9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F2The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.72 to $9.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.75 to $9.735, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F5The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.83 to $9.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F6LKST, Inc. is the general partner of Leukon. Timothy Springer is the president of LKST, Inc. and the managing member of TAS. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
- F7Held by Leukon Investments LP ("Leukon").
- F8Held by TAS Partners, LLC ("TAS").